Literature DB >> 34358065

Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time.

Audrey Fohlen1,2, Karim Bordji1, Eric Assenat3, Céline Gongora4, Céline Bazille1,5, Jérémy Boulonnais1, Mikaël Naveau6, Cécile Breuil7, Elodie A Pérès1, Myriam Bernaudin1, Boris Guiu8.   

Abstract

To treat colorectal liver metastases, intra-arterial chemotherapies may complete therapeutic arsenal. Drugs using intra-arterially are very heterogeneous. The aim of this study was to select the most efficient drug on a panel of colorectal cancer (CRC) cell lines (Caco-2, HCT 116, HT 29, SW 48, SW 480, SW 620) exposed for 30 min to 12 cytotoxic agents (doxorubicin, epirubicin, idarubicin, 5-FU, raltitrexed, gemcitabine, cisplatin, oxaliplatin, mitomycin C, irinotecan, streptozocin, paclitaxel) at different concentrations. The effect on cell viability was measured using the WST-1 cell viability assay. For each drug and cell line, the IC50 and IC90 were calculated, which respectively correspond to the drug concentration (mg/mL) required to obtain 50% and 90% of cell death. We also quantified the cytotoxic index (CyI90 = C Max/IC90) to compare drug efficacy. The main findings of this study are that idarubicin emerged as the most cytotoxic agent to most of the tested CRC cell lines (Caco-2, HT29, HCT116, SW620 and SW480). Gemcitabine seemed to be the most efficient chemotherapy for SW48. Interestingly, the most commonly used cytotoxic agents in the systemic and intra-arterial treatment of colorectal liver metastasis (CRLM) (oxaliplatin, 5-FU, irinotecan) showed very limited cytotoxicity to all the cell lines.

Entities:  

Keywords:  antineoplastic agents; colorectal neoplasms; hepatic artery; in vitro screening; liver neoplasm

Year:  2021        PMID: 34358065     DOI: 10.3390/ph14070639

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  3 in total

1.  Synthesis and Biological Evaluation of Highly Active 7-Anilino Triazolopyrimidines as Potent Antimicrotubule Agents.

Authors:  Paola Oliva; Romeo Romagnoli; Barbara Cacciari; Stefano Manfredini; Chiara Padroni; Andrea Brancale; Salvatore Ferla; Ernest Hamel; Diana Corallo; Sanja Aveic; Noemi Milan; Elena Mariotto; Giampietro Viola; Roberta Bortolozzi
Journal:  Pharmaceutics       Date:  2022-06-02       Impact factor: 6.525

2.  CPDR: An R Package of Recommending Personalized Drugs for Cancer Patients by Reversing the Individual's Disease-Related Signature.

Authors:  Ruzhen Chen; Xun Wang; Xinru Deng; Lanhui Chen; Zhongyang Liu; Dong Li
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

3.  Polo-like kinase 4 is associated with advanced TNM stages and reduced survival and its inhibition improves chemosensitivity in colorectal cancer.

Authors:  Zhengang Duan; Lei Cai; Jin Cao; Wei Wu
Journal:  Oncol Lett       Date:  2022-06-20       Impact factor: 3.111

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.